What is Chugai Pharmaceutical Co Financial Strength?
Chugai Pharmaceutical Co has the Financial Strength Rank of 10. It shows strong financial strength and is unlikely to fall into distressed situations.
Good Sign:
Chugai Pharmaceutical Co Ltd shows strong financial strength.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Chugai Pharmaceutical Co has no long-term debt (1).
Chugai Pharmaceutical Co's debt to revenue ratio for the quarter that ended in Mar. 2024 was 0.00.
As of today, Chugai Pharmaceutical Co's Altman Z-Score is 20.73.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Competitive Comparison of Chugai Pharmaceutical Co's Financial Strength
For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chugai Pharmaceutical Co's Financial Strength Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's Financial Strength distribution charts can be found below:
* The bar in red indicates where Chugai Pharmaceutical Co's Financial Strength falls into.
Chugai Pharmaceutical Co Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Chugai Pharmaceutical Co's Interest Expense for the
months ended in Mar. 2024 was $0 Mil. Its Operating Income for the
months ended in Mar. 2024 was $667 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0 Mil.
Chugai Pharmaceutical Co's Interest Coverage for the quarter that ended in Mar. 2024 is
| Chugai Pharmaceutical Co had no long-term debt (1). |
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Chugai Pharmaceutical Co Ltd has no debt.
2. Debt to revenue ratio. The lower, the better.
Chugai Pharmaceutical Co's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Chugai Pharmaceutical Co has a Z-score of 20.73, indicating it is in Safe Zones. This implies the Z-Score is strong.
Good Sign:
Altman Z-score of 20.73 is strong.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Business Description
Traded in Other Exchanges
Address
1-1 Nihonbashi-Muromachi 2-Chome, Nihonbashi Mitsui Tower (Reception15F), Chuo-ku, Tokyo, JPN, 103-8324
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding Ltd, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and COVID-19.
Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CHGCF has been successfully added to your